A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Sabanathan, Dhanusha (Associate Investigator)

Project: Research

Project Details

AcronymADG116-1003
StatusActive
Effective start/end date14/09/20 → 27/08/25